AUA 2026 Meeting, abstract summaries

[webslave]

Here is a list of papers presenting at the May 2026 American Urological Association meeting relevant to UCPPS (CPPS and IC/BPS). This summary is created by the admin of this site, and is one of the time-consuming services that we perform for the readership.

PD02-01 Is Hunner Lesion-Interstitial Cystitis/Bladder Pain Syndrome (HL-IC/BPS) a B Cell-Driven Autoimmune Disease? A Comprehensive, Population-Based Analysis of Autoimmunity Amongst a Large Cohort of HL-IC/BPS Patients

This population-based analysis evaluated a large cohort of Hunner lesion patients. The study findings show a significant overlap with B cell-driven autoimmune diseases. Ultimately, the results support a B cell-driven autoimmune origin for this inflammatory phenotype of interstitial cystitis/bladder pain syndrome

PD02-03 Study of Changes in Cystoscopy Findings and Hunner Lesion (HL) Profile in Patients of IC/BPS (Interstitial Cystitis/Bladder Pain Syndrome) Who Continue to Suffer Over Years

This study tracks longitudinal changes in cystoscopy profiles for patients with persistent, unresolved symptoms. It shows how the underlying urological and structural presentation of Hunner lesions changes over a multi-year period of chronic pain.

PD02-04 Urinary Proteins Stratify Severe and Non-Severe Patient Phenotypes of Urologic Chronic Pelvic Pain Syndrome (UCPPS): A MAPP Research Network Study

Quantitative urinary proteomic alterations differentiate severe from non-severe UCPPS symptoms with high sensitivity and specificity. These targetable pathway changes offer objective measures of clinical severity and point to actionable upstream inflammatory regulators.

PD02-05 Comprehensive Profiling of Urinary Extracellular Vesicle microRNAs Identifies Novel Diagnostic Biomarkers for IC/BPS

This abstract profiles microRNA expression signatures isolated from urinary extracellular vesicles. The findings outline a valid path toward establishing non-invasive, objective molecular biomarkers to accurately diagnose interstitial cystitis.

PD02-06 Integration of Single-Cell and Spatial Transcriptomic Analyses Reveals Pathogenic Mechanisms in Interstitial Cystitis/Bladder Pain Syndrome

By combining single-cell RNA sequencing with spatial transcriptomics, this study maps the high-resolution tissue architecture of patient bladders. The integration successfully isolates localized cellular drivers behind the development of Hunner-type inflammatory phenotypes.

PD02-07 Molecular Characterization of Chronic Inflammatory Diseases of the Urinary Bladder Based on Next-Generation RNA Sequencing and Digital Image Analysis

This research establishes a definitive molecular characterization framework for chronic inflammatory bladder diseases. Combining deep tissue RNA sequencing with computerized image metrics reveals distinct pathogeneses hidden across similar-looking bladder pathologies.

PD02-08 Corneal Confocal Microscopy as a Novel Biomarker for Chronic Pelvic Pain Syndrome (CPPS)

This investigation tracks small-fiber systemic neurological modifications in patients suffering from severe chronic pelvic pain. It highlights corneal confocal microscopy as an innovative, non-invasive imaging biomarker to gauge neuro-inflammatory disease progression outside the pelvis.

PD02-09 Antler Stem Cell Exosomes Ameliorate Interstitial Cystitis

This regenerative study establishes that antler stem cell-derived exosomes effectively reverse bladder wall inflammation. The bio-active molecules inside these exosomes significantly repair damaged urothelium and downregulate local tissue injury.

PD02-13 Elevated Psychiatric Comorbidity and Polygenic Risk for Depression in Interstitial Cystitis/Bladder Pain Syndrome

This broad genetic risk profile evaluation identifies a strong systemic link between urological pain and psychological issues. The findings conclude there is a significantly elevated polygenic risk overlap matching depression and psychiatric comorbidities in IC/BPS cohorts.

IP14-13 Pathways of Pain: Incidence of Varicocele, Orchialgia, and Prostatitis in Males with Pelvic Floor Dysfunction

This clinical review analyzes cross-over pain paths in male cohorts showing pelvic floor muscle dysfunction. It clarifies that structural pelvic floor disorders correlate heavily with secondary cases of varicocele, prostate irritation, and chronic testicular pain.

IP14-14 From Scrotal Pain to Serotonin Pathways: Duloxetine in Chronic Orchialgia

Evaluating the central nervous system mechanisms of persistent scrotal pain, this study tests chemical neuromodulation. It concludes that the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine is an effective treatment choice for alleviating chronic, treatment-resistant orchialgia.

IP14-15 Physico-Enzymatic Approach for Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

The combination of Extracorporeal Shockwave Therapy (ESWT) and the drug bovhyaluronidase azoximer is safe and highly effective. Long-term analysis verifies this dual mechanical-enzymatic protocol successfully lyses fibrotic regions, dissolves calcifications, and provides lasting pelvic pain relief.

IP14-16 Clinical Characteristics and Outcomes of Men with Chronic Pelvic Pain Syndrome / Chronic Prostatitis (CPPS/CP)

Tracking standard referral treatment choices, this study reviews the multi-tier management of male CPPS. It shows that patient outcomes improve significantly when utilizing standardized, multi-modal clinical pathways including pelvic floor physical therapy and neuromodulation.

IP14-17 Clues to Pain Relief: Treatment and Symptom Patterns in Men with Chronic Pelvic Pain

Patient age, baseline urinary features, and tailored clinical interventions (specifically peripheral nerve blocks and target neuromodulation) directly dictate therapeutic success. Group responders are easily distinguished by localized symptom patterns, supporting individualized management strategies.

IP27-05 Voluntary Exercise Decreases Stress-Induced Bladder Dysfunction

Testing a water avoidance stress (WAS) model, this study concludes that consistent voluntary exercise directly protects the bladder. Exercise limits stress-induced mast cell infiltration, restores tight junction permeability, and significantly lowers local tissue DNA damage and oxidative stress.


You can visit the actual abstracts here:
https://www.auajournals.org/doi/10.1097 ... 4872.fd.01
https://www.auajournals.org/doi/10.1097 ... 4872.fd.03
https://www.auajournals.org/doi/10.1097 ... 4872.fd.04
https://www.auajournals.org/doi/10.1097 ... 4872.fd.05
https://www.auajournals.org/doi/10.1097 ... 4872.fd.06
https://www.auajournals.org/doi/10.1097 ... 4872.fd.07
https://www.auajournals.org/doi/10.1097 ... 4872.fd.08
https://www.auajournals.org/doi/10.1097 ... 4872.fd.09
https://www.auajournals.org/doi/10.1097 ... 4872.fd.13
https://www.auajournals.org/doi/10.1097 ... 3132.27.13
https://www.auajournals.org/doi/10.1097 ... 3132.27.14
https://www.auajournals.org/doi/10.1097 ... 3132.27.15
https://www.auajournals.org/doi/10.1097 ... 3132.27.16
https://www.auajournals.org/doi/10.1097 ... 3132.27.17
https://www.auajournals.org/doi/10.1097 ... 8373.9b.05